Avicanna Inc. (TSX: AVCN)

Market Cap	34.27M
Revenue (ttm)	22.07M
Net Income (ttm)	-6.55M
Shares Out	97.60M
EPS (ttm)	-0.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	212,910
Open	0.400
Previous Close	0.400
Day's Range	n/a
52-Week Range	0.200 - 0.600
Beta	1.54
Analysts	n/a
Price Target	0.70 (+100.0%)
Earnings Date	Aug 13, 2024

About Avicanna

Avicanna Inc., a commercial-stage biopharmaceutical company, engages in the research, development, advancement, and commercialization of evidence-based cannabinoid-based products and formulations for consumer, medical, and pharmaceutical markets worldwide. It commercializes approximately thirty proprietary evidence-based finished products. The company provides medical cannabis formulary products, including oral, sublingual, topical, and transdermal deliveries with various ratios of cannabinoids under the RHO Phyto brand; and indication-specific...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Aras Azadian B.Econ, Mba
• Employees: 87
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: AVCN

Financial Performance

In 2023, Avicanna's revenue was 16.79 million, an increase of 314.82% compared to the previous year's 4.05 million. Losses were -7.89 million, -54.21% less than in 2022.